A) The activity of circulating 12/15-LO was not altered during diabetes as indicated by no significant changes in the plasma levels of major metabolites derived from 12/15-lipoxygenation of different PUFAs, including LA (9- and 13-HODEs), AA (12- and 15- HETEs), EPA (12- and 15- HEPEs), or DHA (14- and 17-HDoHE). B) In contrast to 12/15-LO metabolites, levels of CYP/sEH metabolites derived from different PUFAs showed an increasing trend in diabetes. This trend was significantly evident among 9,10-DiHOME, 5,6-DiHETrE, 11,12-DiHETrE, 14,15-DiHETrE. Data shown for the comparison are from the same experimental groups used in figure 1 and represented here by the mean fold change of 6 diabetic mice relative to the average of 8 nondiabetic mice ± SD.